HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A

International Journal of Cancer

Volumn 129, Issue 9, 2011, Pages 2104-2114

  Lee, Sang Y ^a   Liu, Siying ^a   Mitchell, Ryan M ^a   Slagle Webb, Becky ^a   Hong, Young Soo ^b   Sheehan, Jonas M ^a   Connor, James R ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

glioma; HFE polymorphism; HSP90 inhibitor; neuroblastoma; p16INK4A; temozolomide (Temodar)

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOXORUBICIN; GELDANAMYCIN; GLYCOPROTEIN P; HEAT SHOCK PROTEIN 70; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P16; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TEMOZOLOMIDE;

ARTICLE; ASTROCYTOMA CELL; CANCER RESISTANCE; CELL CYCLE ARREST; CONTROLLED STUDY; GAMMA RADIATION; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLIOMA CELL; HFE GENE; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PHARMACOGENETICS; PRIORITY JOURNAL; RADIOSENSITIVITY;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLIOMA; HISTOCOMPATIBILITY ANTIGENS CLASS I; HSP72 HEAT-SHOCK PROTEINS; HUMANS; MEMBRANE PROTEINS; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASMS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RADIATION TOLERANCE; TUMOR SUPPRESSOR PROTEINS;

EID: 80052264607     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25888     Document Type: Article

References (50)

1. Hellerbrand C, Poppl A, Hartmann A, Scholmerich J, Lock G,. HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence. Clin Gastroenterol Hepatol 2003; 1: 279-84. (Pubitemid 37254455)
2. Wu T, Sempos CT, Freudenheim JL, Muti P, Smit E,. Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. Ann Epidemiol 2004; 14: 195-201. (Pubitemid 38249333)
3. Miyata Y, Koga S, Nishikido M, Hayashi T, Kanetake H,. Relationship between serum ferritin levels and tumour status in patients with renal cell carcinoma. BJU Int 2001; 88: 974-7. (Pubitemid 34099029)
4. Sato Y, Honda Y, Asoh T, Oizumi K, Ohshima Y, Honda E,. Cerebrospinal fluid ferritin in glioblastoma: evidence for tumor synthesis. J Neurooncol 1998; 40: 47-50. (Pubitemid 28548371)
5. Weber A, Engers R, Nockemann S, Gohr LL, Zur Hausen A, Gabbert HE,. Differentially expressed genes in association with in vitro invasiveness of human epithelioid sarcoma. Mol Pathol 2001; 54: 324-30. (Pubitemid 32928259)
6. Moriwaki H, Osborne MR, Phillips DH,. Effects of mixing metal ions on oxidative DNA damage mediated by a Fenton-type reduction. Toxicol In Vitro 2008; 22: 36-44. (Pubitemid 350267103)
7. Freitas I, Boncompagni E, Vaccarone R, Fenoglio C, Barni S, Baronzio GF,. Iron accumulation in mammary tumor suggests a tug of war between tumor and host for the microelement. Anticancer Res 2007; 27: 3059-65. (Pubitemid 47607527)
8. Yang DC, Jiang X, Elliott RL, Head JF,. Antisense ferritin oligonucleotides inhibit growth and induce apoptosis in human breast carcinoma cells. Anticancer Res 2002; 22: 1513-24. (Pubitemid 34839158)
9. Feder JN, Penny DM, Irrinki A, Lee VK, Lebron JA, Watson N, Tsuchihashi Z, Sigal E, Bjorkman PJ, Schatzman RC,. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 1998; 95: 1472-7. (Pubitemid 28103416)
10. Lebron JA, West AP, Jr, Bjorkman PJ,. The hemochromatosis protein HFE competes with transferrin for binding to the transferrin receptor. J Mol Biol 1999; 294: 239-45.
11. Beutler E,. Hemochromatosis: genetics and pathophysiology. Annu Rev Med 2006; 57: 331-47. (Pubitemid 43263092)
12. Sampietro M, Caputo L, Casatta A, Meregalli M, Pellagatti A, Tagliabue J, Annoni G, Vergani C,. The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease. Neurobiol Aging 2001; 22: 563-8. (Pubitemid 32607740)
13. Jin F, Qu LS, Shen XZ,. Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: a meta-analysis. J Exp Clin Cancer Res 2010; 29: 18.
14. Osborne NJ, Gurrin LC, Allen KJ, Constantine CC, Delatycki MB, McLaren CE, Gertig DM, Anderson GJ, Southey MC, Olynyk JK, Powell LW, Hopper JL, et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology 2010; 51: 1311-18.
15. Davis CF, Dorak MT,. An extensive analysis of the hereditary hemochromatosis gene HFE and neighboring histone genes: associations with childhood leukemia. Ann Hematol 2010; 89: 375-84.
16. Dorak MT, Burnett AK, Worwood M,. HFE gene mutations in susceptibility to childhood leukemia: HuGE review. Genet Med 2005; 7: 159-68. (Pubitemid 40478152)
17. Gannon PO, Medelci S, Le Page C, Beaulieu M, Provencher DM, Mes-Masson AM, Santos MM,. Impact of hemochromatosis gene (HFE) mutations on epithelial ovarian cancer risk and prognosis. Int J Cancer, in press.
18. Connor JR, Lee SY,. HFE mutations and Alzheimer's disease. J Alzheimers Dis 2006; 10: 267-76. (Pubitemid 44763997)
19. Wang XS, Lee S, Simmons Z, Boyer P, Scott K, Liu W, Connor J,. Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. J Neurol Sci 2004; 227: 27-33. (Pubitemid 39491122)
20. Lee SY, Patton SM, Henderson RJ, Connor JR,. Consequences of expressing mutants of the hemochromatosis gene (HFE) into a human neuronal cell line lacking endogenous HFE. FASEB J 2007; 21: 564-76. (Pubitemid 46213503)
21. Mitchell RM, Lee SY, Randazzo WT, Simmons Z, Connor JR,. Influence of HFE variants and cellular iron on monocyte chemoattractant protein-1. J Neuroinflamm 2009; 6: 6.
22. Hall EC, II, Lee SY, Simmons Z, Neely EB, Nandar W, Connor JR,. Prolyl-peptidyl isomerase, Pin1, phosphorylation is compromised in association with the expression of the HFE polymorphic allele, H63D. Biochim Biophys Acta 2010; 1802: 389-95.
23. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96. (Pubitemid 40349501)
24. Kurz EU, Douglas P, Lees-Miller SP,. Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J Biol Chem 2004; 279: 53272-81. (Pubitemid 40051831)
25. Wong C, Chen S,. Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance. Cancer Res 2009; 69: 8670-7.
26. Stravopodis DJ, Margaritis LH, Voutsinas GE,. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. Curr Med Chem 2007; 14: 3122-38. (Pubitemid 350226961)
27. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA,. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000; 60: 5954-8.
28. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ,. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997; 34: 275-8. (Pubitemid 27208030)
29. Middlemas DS, Stewart CF, Kirstein MN, Poquette C, Friedman HS, Houghton PJ, Brent TP,. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 2000; 6: 998-1007. (Pubitemid 30159360)
30. Li Y, Yin W, Wang X, Zhu W, Huang Y, Yan G,. Cholera toxin induces malignant glioma cell differentiation via the PKA/CREB pathway. Proc Natl Acad Sci USA 2007; 104: 13438-43. (Pubitemid 47293963)
31. INK4α expression in human diploid fibroblasts. J Cell Sci 2008; 121: 2235-45.
32. Kanzawa T, Germano IM, Kondo Y, Ito H, Kyo S, Kondo S,. Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. Br J Cancer 2003; 89: 922-9. (Pubitemid 37175817)
33. Uzzaman M, Keller G, Germano IM,. Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells. J Neurosurg 2007; 106: 646-51. (Pubitemid 46536462)
34. Gaspar N, Sharp SY, Pacey S, Jones C, Walton M, Vassal G, Eccles S, Pearson A, Workman P,. Acquired resistance to 17-allylamino-17- demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res 2009; 69: 1966-75.
35. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, Dallenbach-Hellweg G, Schmidt D, von Knebel Doeberitz M,. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92: 276-84. (Pubitemid 32225381)
36. Murphy N, Ring M, Heffron CC, King B, Killalea AG, Hughes C, Martin CM, McGuinness E, Sheils O, O'Leary JJ,. p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol 2005; 58: 525-34. (Pubitemid 40646875)
37. Ivanova TA, Golovina DA, Zavalishina LE, Volgareva GM, Katargin AN, Andreeva YY, Frank GA, Kisseljov FL, Kisseljova NP,. Up-regulation of expression and lack of 5′ CpG island hypermethylation of p16 INK4a in HPV-positive cervical carcinomas. BMC Cancer 2007; 7: 47.
38. Lau WM, Ho TH, Hui KM,. p16INK4A-silencing augments DNA damage-induced apoptosis in cervical cancer cells. Oncogene 2007; 26: 6050-60. (Pubitemid 47373800)
39. Zhang J, Stevens MF, Laughton CA, Madhusudan S, Bradshaw TD,. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. Oncology 2010; 78: 103-14.
40. Schulte TW, Akinaga S, Soga S, Sullivan W, Stensgard B, Toft D, Neckers LM,. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones 1998; 3: 100-8. (Pubitemid 28327422)
41. Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dai Z, Reinhold WC, Papp A, Weinstein JN, Sadee W,. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 2004; 64: 4294-301. (Pubitemid 38802436)
42. McCollum AK, TenEyck CJ, Stensgard B, Morlan BW, Ballman KV, Jenkins RB, Toft DO, Erlichman C,. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. Cancer Res 2008; 68: 7419-27.
43. Schweigerer L, Rave-Frank M, Schmidberger H, Hecht M,. Sublethal irradiation promotes invasiveness of neuroblastoma cells. Biochem Biophys Res Commun 2005; 330: 982-8. (Pubitemid 40462182)
44. McConnell BB, Gregory FJ, Stott FJ, Hara E, Peters G,. Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes. Mol Cell Biol 1999; 19: 1981-9. (Pubitemid 29098256)
45. Puduvalli VK, Kyritsis AP, Hess KR, Bondy ML, Fuller GN, Kouraklis GP, Levin VA, Bruner JM,. Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival. Int J Oncol 2000; 17: 963-9.
46. Conscience I, Jovenin N, Coissard C, Lorenzato M, Durlach A, Grange F, Birembaut P, Clavel C, Bernard P,. P16 is overexpressed in cutaneous carcinomas located on sun-exposed areas. Eur J Dermatol 2006; 16: 518-22. (Pubitemid 44861826)
47. Majid S, Kikuno N, Nelles J, Noonan E, Tanaka Y, Kawamoto K, Hirata H, Li LC, Zhao H, Okino ST, Place RF, Pookot D, et al. Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res 2008; 68: 2736-44. (Pubitemid 351556271)
48. Gomez-Manzano C, Lemoine MG, Hu M, He J, Mitlianga P, Liu TJ, Yung AW, Fueyo J, Groves MD,. Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. Int J Oncol 2001; 19: 359-65.
49. Hama S, Heike Y, Naruse I, Takahashi M, Yoshioka H, Arita K, Kurisu K, Goldman CK, Curiel DT, Saijo N,. Adenovirus-mediated p16 gene transfer prevents drug-induced cell death through G1 arrest in human glioma cells. Int J Cancer 1998; 77: 47-54. (Pubitemid 28308551)
50. Grim J, D'Amico A, Frizelle S, Zhou J, Kratzke RA, Curiel DT,. Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel. Clin Cancer Res 1997; 3: 2415-23. (Pubitemid 28133163)